6 September 2023 - Oncology experts celebrated the joint reimbursement of Opdivo together with its PD-L1 IHC 28-8 PharmDx companion ...
21 August 2023 - Drug price negotiations for two spinal muscular atrophy drugs --Spinraza (nusinersen sodium) and Evrysdi (risdiplam) – ...
25 July 2023 - Merck’s anti-PD-L1 immuno-oncology drug Bavencio (avelumab) will get insurance coverage starting next month as first-line maintenance ...
7 July 2023 - Teva Handok's severe asthma treatment Cinqair (reslizumab) crossed the threshold of the Drug Benefit Evaluation Committee ...
11 July 2023 - A Korean doctor expressed excitement that patients suffering from severe atopic dermatitis will be able to ...
3 July 2023 - Korean-born expert in Canada stresses appropriate reimbursement for biological drugs. ...
30 June 2023 - Novartis' Scemblix (asciminib) will receive reimbursement for the third-line or more treatment of chronic myeloid leukaemia ...
22 June 2023 - In the first half of 2023, the Ministry of Health and Welfare set up a public ...
2 June 2023 - The nation’s health insurance review agency said Roche's Evrysdi (risdiplam), an oral treatment for spinal muscular ...
2 May 2023 - Beigene Korea said Monday that its Brukinsa 80 mg capsules (zanubrutinib) began to receive insurance benefits ...
1 June 2023 - BMS Korea has announced that Inrebic (fedratinib), its myelofibrosis drug, will now be covered by the ...
19 May 2023 - Spinal muscular atrophy patients taking Spinraza (nusinersen sodium) are protesting against the Health Insurance Review and ...
16 May 2023 - Astellas Pharma has set about to rectify the reimbursement track for Xtandi (enzalutamide), its prostate cancer ...
9 May 2023 - Opdivo (nivolumab), an anti-PD-1 immunotherapy, will likely receive insurance benefits soon as the primary treatment of ...
27 April 2023 - Several targeted agents for lung cancer approved through fast-track review due to their innovativeness and urgency ...